[1]
Natural Product as Anticancer Agents. Current status and future persepective. Molecules 2022; 27(23): 8367.
[9]
Dickens E, Ahmed S. Principles of cancer treatment by chemotherapy. Surgery 2018; 36: 134-8.
[24]
Dharmendra K, Pramod SK, Use T. Phytochemicals and pharmacological activity of salvadora persica: A review. Curr Nutr Food Sci 2021; 17(3)
[33]
Man-Yi W. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model Nanomedicine: Nanotechnology. Biol Med 2011; 7: 834-40.
[35]
YuangangZu Y. Optimization of the preparation process of vinblastine sulfate (VBLS)-loaded folate conjugated bovine serum albumin (BSA) nanoparticles for tumor-targeted drug delivery using response surface methodology (RSM). Int J Nanomedicine 2009; 10.
[36]
Jieru L. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octa sulfate as drug trapping agent. Int J Pharm 2019; 557: 264-72.
[37]
Kazemabadi Fatemeh Zare, Heydarinasab Amir, Akbarzadeh Azim, Preparation Mehdi Ardjmand. Preparation, characterization and In vitro evaluation of PEGylated nano liposomal containing etoposide on lung cancer. Artif Cells Nanomed Biotechnol 2019; 47(1): 3222-30.
[42]
Meng Jie, Guo Fangqin, Xu Haiyan, Wei Liang, Wang Chen. Combination therapy using co-encapsulated resveratrol and paclitaxel in liposomes for drug resistance reversal in breast cancer cells In vivo. Sci Rep 2016; 6: 22390.
[44]
Ali Z. Synthesis of curcumin loaded smart pH-responsive stealth liposome as a novel nanocarrier for cancer treatment. Fiber 2021; 9(3): 19.
[45]
Chishti N. Preparation, optimization, and In vivo evaluation of nanoparticle-based formulation for pulmonary delivery of anticancer drug. Medicina 2019; 55(6): 294.
[46]
Bao Y, Deng Q, Li Y, Zhou S. Engineering docetaxel-loaded micelles for nonsmall cell lung cancer: A comparative study of microfluidic and bulk nanoparticle preparation. RSC Advances 2018; 8(56): 31950-66.
[47]
Silva EJ. Development of Topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Eur J Pharm Biopharm 2011; 79: 189-96.
[48]
Borhaneh Hasan N. A promising targeting system to enrich irinotecan antitumor efficacy: Folic acid targeted nanoparticles. J Drug Deliv Sci Technol 2021; 63: 102543.
[50]
Yury A. Development of drug delivery systems for taxanes using ionic gelation of carboxyacyl derivatives of chitosan. Carbohydr Polym 2017; 162(15): 49-55.
[51]
Zhang L, Yang M, Wang Q, Li Y. 10-Hydroxycamptothecin loaded nanoparticles: Preparation and antitumor activity in mice. J Control Release 2007; 119(2): 153-62.
[53]
Yua Mian, Zhaob Miaoqing, Yua Rilei, Chua Shaochen, Xua Jiahao, Xiad Ming. Nanotechnology-mediated immunochemotherapy with ingenol-3-mebutate for systematic anti-tumor effects. J Control Release 2019; 304: 242-58.
[55]
Ozgur E. Influence of emulsifiers on the formation and In vitro anticancer activity of epirubicin loaded PLGA nanoparticles. J Drug Deliv Sci Technol 2020; 60: 102027.
[57]
Fariza Aina AM. Drug release profiles of mitomycin c encapsulated quantum dots-chitosan nanocarrier system for the possible treatment of non-muscle invasive bladder cancer. Pharmaceutics 2021; 13(9): 1379.
[58]
Ghassan M. Hesperidin loaded on gold nanoparticles as a drug delivery system for a successful biocompatible, anti-cancer, antiinfammatory and phagocytosis inducer model. Sci Report 2020; 10(1): 9362.
[59]
Oscar E-R. Rapamycin-loaded polysorbate 80-coated PLGA nanoparticles: Optimization of formulation variables and In vitro anti-glioma assessment. J Drug Deliv Sci Technol 2019; 52: 488-99.
[60]
Dog A. Bleomycin loaded magnetic chitosan nanoparticles as, multifunctional nanocarriers. J Bioact Compat Polym 2010; 25(3): 305-18.
[62]
Dharmendra K, Pramod SK. Quercetin: A comprehensive review. Curr Nutr Food Sci 2023; 19.
[64]
Khatoon E, Banik K, Harsha C, et al. Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives. In: Seminars in Cancer Biology. Cambridge, MA, USA: Academic Press 2020.
[71]
Dharmendra Kumar, Pramod Sharma Kumar. Formulation and evaluation of quercetin-loaded banana starch nanoparticles. Nanosci Nanotechnol Asia 2023; 13: e240523217291.
[74]
Dharmendra K, Pramod SK. A review on opuntia species and its chemistry, pharmacognosy, pharmacology and bioapplications. Curr Nutr Food Sci 2020; 16(8)
[82]
Fang F, Xiao W, Tian ZNK. Cell-based immunotherapy for cancer. In: seminars in immunology. Cambridge, MA, USA: Academic Press 2017; pp. 37-54.
[128]
Clinical trial of lurbinectedin (PM01183)/doxorubicin versus CAV or topotecan as treatment in patients with small-cell lung cancer (ATLANTIS). NCT02566993, 2021.
[129]
Adavosertib and irinotecan hydrochloride in treating younger patients with relapsed or refractory solid tumors. NCT02095132, 2014.
[130]
Effect of quercetin on green tea polyphenol uptake in prostate tissue from patients with prostate cancer undergoing surgery. NCT01912820, 2021.
[131]
Combination of hydroxyurea and verapamil for refractory meningiomas
[132]
A study of neoadjuvant nivolumab + palbociclib + anastrozole in post-menopausal women and men with primary breast cancer. NCT04075604, 2022.
[133]
A study in second line metastatic colorectal cancer. NCT01183780, 2015.
[134]
Dinutuximab and irinotecan versus irinotecan to treat subjects with relapsed or refractory small cell lung cancer. NCT03098030, 2021.
[135]
Paclitaxel-induced polyneuropathy in breast cancer: Early detection, risk factors, quality of life and lifestyle outcomes (CIPNREBECCA). NCT06052345, 2023.
[136]
A safety and efficacy study of BCD-022 with paclitaxel compared to herceptin with paclitaxel in HER2+ metastatic breast cancer patients. NCT01764022, 2018.
[137]
Topotecan hydrochloride or cyclodextrin-based polymercamptothecin CRLX101 in treating patients with recurrent small cell lung cancer. NCT01803269, 2020.
[138]
Combining CRLX101, a nanoparticle camptothecin, with enzalutamide in people with progressive metastatic castration-resistant prostate cancer following prior enzalutamide treatment. NCT03531827, 2022.
[139]
A phase 2 study of CRLX101(NLG207) in patients with advanced non-small cell lung cancer. NCT01380769, 2017.
[140]
Neoadjuvant chemoradiotherapy with CRLX-101 and capecitabine for rectal cancer - study results.
[141]
Green tea extract in treating patients with monoclonal gammopathy of undetermined significance and/or smoldering multiple myeloma. NCT00942422, 2015.
[142]
Fish oil and green tea extract in preventing prostate cancer in patients who are at risk for developing prostate cancer. NCT00253643, 2017.
[143]
Pazopanib and paclitaxel as first-line treatment for subjects with unresectable stage III and stage IV melanoma.
[144]
Safety study of pertuzumab (in combination with trastuzumab and docetaxel) in Indian participants with breast cancer.
[145]
A phase III trial of ZD4054 (zibotentan) (endothelin a antagonist) in hormone resistant prostate cancer with bone metastases (ENTHUSE M1). NCT00554229, 2016.
[146]
Proton beam radiation therapy and chemotherapy in treating patients with stage iii non-small cell lung cancer that can be removed by surgery; NCT01076231, 2021.
[147]
Cisplatin and etoposide with or without veliparib in treating patients with extensive stage small cell lung cancer. NCT01642251, 2019.
[166]
Stewart B, Wild CP. World Cancer Report 2014. Geneva, Switzerland: World Health Organization 2014.
[202]
Kwak H-H, Kim I-R, Kim H-J, Park B-S, Yu S-B. α mangostin induces apoptosis and cell cycle arrest in oral squamous cell carcinoma cell. Evid Based Complement Altern Med 2016; p. 9060649.
[245]
Kashyap D, Tuli HS, Yerer MB, et al. Natural product-based nanoformulations for cancer therapy: Opportunities and challenges. In: Seminars in Cancer Biology. Cambridge, MA, USA: Academic Press 2019.